Gonadotropin releasing hormone agonists: Expanding vistas
Gonadotropin-releasing hormone (GnRH) agonists are derived from native GnRH by amino acid substitution which yields the agonist resistant to degradation and increases its half-life. The hypogonadotropic hypogonadal state produced by GnRH agonists has been often dubbed as “pseudomenopause” or “medica...
Main Author: | Magon, Navneet |
---|---|
Format: | Online |
Language: | English |
Published: |
Medknow Publications
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193774/ |
Similar Items
-
Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
by: Keane, Fergus, et al.
Published: (2016) -
Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
by: Shiasi Arani, Kobra, et al.
Published: (2015) -
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
by: Jumpei Asakawa, et al.
Published: (2018-07-01) -
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
by: Choi, Seungtaek, et al.
Published: (2011) -
Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
by: Han, Eun Jin, et al.
Published: (2013)